A federal judge in Charlottesville on Friday, July 24, 2026, ruled that a Biden-era rule that forced doctors and pharmacies to obtain special certification before prescribing the abortion drug mifepristone was unlawful, sending the disputed restriction back to federal regulators for a do-over. The lawsuit, brought by abortion providers, argued the 2023 certification requirement would make it harder to provide medication abortions. The judge stopped short of touching the FDA's overall approval of mifepristone and instead ordered the agency to either better explain and justify the rule or revise it.
What the judge found
U.S. District Judge Robert Ballou found that the Food and Drug Administration had not adequately explained why prescriber and pharmacy certification was necessary under the Administrative Procedure Act, and he criticized the agency for failing to show how scrapping those requirements would create “an intolerable risk.” As reported by Reuters, Ballou sided with three abortion providers that challenged the 2023 changes.
The lawsuit behind the order
The case, filed in 2023 by independent abortion providers, targeted parts of the Risk Evaluation and Mitigation Strategy (REMS) that added provider registration, pharmacy certification and a mandatory patient acknowledgement form. Court records and prior opinions trace how the REMS evolved, and the plaintiffs argue those added steps burden patients and clinicians without medical justification. The case docket and earlier Ballou memoranda can be found on Justia.
How this fits in the wider fight
The Charlottesville ruling lands in the middle of a maze of mifepristone lawsuits that have bounced through federal courts, including a much-watched appeals court order this spring that briefly threatened mail-order and telehealth access. That emergency move triggered a short-term intervention by the Supreme Court earlier this year and forced providers to scramble contingency plans as the rules kept shifting. For a reminder of that earlier clash, see the Supreme Court pause on mail-order in local coverage.
What it means for patients
Medication abortion already accounts for a majority of clinician-provided abortions, with the Guttmacher Institute estimating that about 63% of such care in 2023 relied on pills. That share is a big reason why even incremental federal rule changes can ripple through access on the ground. Ballou’s order forces the FDA to revisit the 2023 REMS adjustments at the same time the agency is carrying out a broader review of mifepristone’s safety, a combination that could lead to more rulemaking or another round of courtroom battles. The Guttmacher Institute has background on both the numbers and the ongoing agency review.
What happens next
On paper, Ballou has sent the issue back into the administrative process, which means the FDA must now either defend its REMS choices in court with a fuller explanation or change the rule and justify a new version. Either path is expected to spawn more briefing and likely appeals. Legal observers note that this ruling joins a cluster of related mifepristone cases that are already on appeal or on hold, so a final resolution could be months away. For now, the order is procedural: it demands a clearer explanation from the agency and keeps mifepristone available while the larger fight plays out, with the Georgetown litigation tracker following the status and filings.
